Delineating associations of progressive pleuroparenchymal fibroelastosis in patients with pulmonary fibrosis

Eyjólfur Gudmundsson, An Zhao, Nesrin Moğulkoç, Frouke van Beek, Tinne Goos, Christopher J. Brereton, Marcel Veltkamp, Robert Chapman, Hendrik W. van Es, Helen Garthwaite, Bahareh Gholipour, Melissa Heightman, Arjun Nair, Katarina Pontoppidan, Recep Savaş, Asia Ahmed, Marie Vermant, Ömer Selim Unat, Alex Procter, Laurens De Sadeleer, Emma Denneny, T Wallis, Mark Duncan, Magali N. Taylor, Stijn E. Verleden, Sam M. Janes, Daniel C. Alexander, Athol U. Wells, Joanna C. Porter, Mark G. Jones, Iain Stewart, Coline H.m. van Moorsel, Wim Wuyts, Joseph JacobERJ 2023 · DOI

TL;DR

This study introduces a computational method to track the progression of pleuroparenchymal fibroelastosis (PPFE) in lung CT scans. They found that worsening PPFE is a significant predictor of mortality in patients with idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (FHP), independent of traditional measures of lung fibrosis progression. This suggests PPFE might represent a distinct, prognostically important disease process.

What Problem Does This Paper Address?

Idiopathic pulmonary fibrosis (IPF) is a serious, progressive lung disease with a variable course. While imaging techniques like CT scans are crucial for diagnosis and monitoring, quantifying disease progression has been challenging. Traditional methods, like visual assessment of lung fibrosis patterns, often show limited correlation with patient outcomes and mortality. Pleuroparenchymal fibroelastosis (PPFE), a specific radiological pattern characterized by dense, upper-lobe pleural-based opacities, has been observed to associate with reduced survival in IPF. However, understanding its progression and its independent prognostic value, especially in comparison to established fibrotic changes, has been limited. This paper aims to address this by developing and validating a computational approach to quantify PPFE progression and assess its impact on mortality in IPF and fibrotic hypersensitivity pneumonitis (FHP) patients.

Methods

The researchers utilized a retrospective cohort of patients with IPF and FHP who had at least two volumetric CT scans taken 6-36 months apart. They employed a computer-based method to quantify PPFE-like lesions, focusing on the upper lung zones. This method calculates the annualised change in computerised upper-zone pleural surface area affected by PPFE (A-PPFE). To account for scan noise and variability, they defined "progressive PPFE" as an A-PPFE exceeding 1.25% per year, a threshold derived from previous studies.

They then used linear mixed-effects models to investigate associations between A-PPFE and changes in visual interstitial lung disease (ILD) extent and forced vital capacity (FVC) decline. Crucially, they employed multivariable Cox regression models to assess the independent association of A-PPFE (and a noise-adjusted version, A-PPFE-adj) with mortality, adjusting for various clinical and radiological factors including age, sex, smoking history, emphysema, antifibrotic use, baseline ILD extent, and baseline PPFE presence.

Datasets

The study utilized data from two patient cohorts:

  • IPF cohort: 414 patients with idiopathic pulmonary fibrosis.
  • FHP cohort: 98 patients with fibrotic hypersensitivity pneumonitis.

These patients were recruited from five medical centers. The data included two volumetric CT examinations per patient, separated by 6-36 months, along with clinical information such as pulmonary function tests. No new benchmark datasets were introduced; the study focused on analyzing existing patient data.

Key Insights and Ideas

  • PPFE Progression as a Distinct Prognostic Factor: The most significant finding is that the progression of PPFE, as quantified by computer analysis, is a strong and independent predictor of mortality in both IPF and FHP. This suggests that PPFE is not merely a bystander finding but actively contributes to poor outcomes.
  • Disassociation from Traditional Fibrosis Measures: The study highlights that PPFE progression shows only weak associations with measures of established lung fibrosis progression, such as changes in ILD extent on CT or FVC decline. This supports the idea that PPFE might arise from different pathophysiological mechanisms than typical fibrotic lung diseases, potentially representing a separate "endotype."
  • Computational Quantification's Value: The use of computer-based quantification of PPFE progression proved effective in identifying a significant prognostic marker, potentially offering greater sensitivity and objectivity than visual assessment alone.
  • Prevalence of Progressive PPFE: A substantial proportion of patients (21-26%) in both cohorts exhibited progressive PPFE, underscoring its clinical relevance.

Key Results

  • Mortality Association: Progressive PPFE (A-PPFE >1.25%/year) was independently associated with increased mortality in both the IPF cohort (Hazard Ratio [HR] 1.25, 95% CI 1.16–1.34, p<0.0001) and the FHP cohort (HR 1.16, 95% CI 1.00–1.35, p=0.045). This association remained significant even after adjusting for baseline PPFE presence and ILD progression.
  • Weak Correlation with Fibrosis Progression: A-PPFE showed only weak associations with changes in ILD extent and FVC decline in multivariable models.
  • Prevalence: 21.5% of the IPF cohort and 25.5% of the FHP cohort demonstrated progressive PPFE.

Limitations and Future Work

  • Retrospective Design and Scan Variability: The study acknowledges the retrospective nature of the data and the inherent variability in CT acquisition parameters (scanner model, reconstruction algorithm, patient inspiration, positioning). While they attempted to account for noise, this remains a potential source of bias.
  • Exclusion Criteria: Patients with acute exacerbations, infections, pneumothoraces, or lung malignancies were excluded. This might lead to an underestimation of progressive PPFE prevalence in the broader patient population, as these conditions can be associated with PPFE.
  • Immunomodulatory Therapies: Detailed information on the use of immunomodulatory therapies was not available, which could have influenced PPFE progression.
  • Future Directions: The authors suggest that computer-based quantification of PPFE progression could serve as a valuable endpoint in future clinical trials for novel therapies targeting PPFE, potentially improving trial power and efficiency. Further research into the specific mechanisms driving PPFE progression and the development of targeted treatments is warranted.

Summary updated

Abstract

Progression of PPFE-like lesions independently associates with mortality in IPF and FHP but does not associate strongly with measures of fibrosis progression.
BibTeX
@inproceedings{gudmundsson2023delineating,
  author = {Eyjólfur Gudmundsson and An Zhao and Nesrin Moğulkoç and Frouke van Beek and Tinne Goos and Christopher J. Brereton and Marcel Veltkamp and Robert Chapman and Hendrik W. van Es and Helen Garthwaite and Bahareh Gholipour and Melissa Heightman and Arjun Nair and Katarina Pontoppidan and Recep Savaş and Asia Ahmed and Marie Vermant and Ömer Selim Unat and Alex Procter and Laurens De Sadeleer and Emma Denneny and T Wallis and Mark Duncan and Magali N. Taylor and Stijn E. Verleden and Sam M. Janes and Daniel C. Alexander and Athol U. Wells and Joanna C. Porter and Mark G. Jones and Iain Stewart and Coline H.M. van Moorsel and Wim Wuyts and Joseph Jacob},
  title = {{Delineating associations of progressive pleuroparenchymal fibroelastosis in patients with pulmonary fibrosis}},
  booktitle = {ERJ},
  year = {2023},
  doi = {10.1183/23120541.00637-2022},
}
Figure